Ohio
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Ohio: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Ohio follows a similar stance as the federal courts regarding the patentability of genetic materials in light of the Myriad decision. The state emphasizes the principle that naturally occurring genes and phenomena cannot be patented if not altered by human intervention.
In Ohio, the patentability of genetic sequences is analyzed under Ohio Revised Code Section 5502.03, which aligns with federal standards established by the Myriad case, emphasizing that isolated DNA is not patentable unless transformed into a non-naturally occurring product.
The court ruled that claims to isolated genetic material were not patentable, echoing the principles laid out in Myriad Genetics.
This case confirmed the threshold that practical utility and human intervention are necessary for patenting items related to genes.
The court held that patents on naturally existing elements are invalid unless substantial human modification is present.
Ohio's approach to genetic patenting issues mirrors the federal stance in 'Myriad,' focusing on the lack of patentability for naturally occurring substances. However, state courts may have slightly different interpretations concerning local statutes, emphasizing the applicability of Ohio-specific laws in conjunction with federal precedents.
Understanding the implications of Myriad in Ohio patent law is relevant for bar exam candidates, particularly in sections covering Intellectual Property, as it addresses key topics such as patent eligibility and the nuances of genetic material.